X4 Pharmaceuticals (XFOR) EPS (Weighted Average and Diluted) (2020 - 2025)
X4 Pharmaceuticals (XFOR) reported EPS (Weighted Average and Diluted) of $1.0 for Q4 2025, up 116.84% on a YoY basis from $0.46 in Q4 2024, and up 244.93% quarter-over-quarter from -$0.69 in Q3 2025.
X4 Pharmaceuticals (XFOR) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at $1.0 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 116.84% year-over-year to $1.0; the trailing twelve-month figure through Dec 2025 stood at -$3.12 (up 44.48% YoY), and the FY2025 full-year result was -$1.87, up 66.55% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at $1.0, up from -$0.69 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $13.57 in Q2 2024, with the low at -$16.59 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.65 across 5 years, with a median of -$0.64 in 2025.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 4212.12% in 2024 against a maximum downside of 54700.0% in 2024.
- X4 Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.28 in 2021, then surged by 84.38% to -$0.2 in 2022, then slumped by 8195.0% to -$16.59 in 2023, then jumped by 64.2% to -$5.94 in 2024, then surged by 116.84% to $1.0 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at $1.0 (Q4 2025), -$0.69 (Q3 2025), and -$3.47 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 0.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -0.61 |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | 1.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 |
| Sep 30, 2025 | -0.69 |
| Jun 30, 2025 | -3.47 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | -5.94 |
| Sep 30, 2024 | -5.48 |
| Jun 30, 2024 | 13.57 |
| Mar 31, 2024 | -7.77 |
| Dec 31, 2023 | -16.59 |
| Sep 30, 2023 | -0.01 |
| Jun 30, 2023 | -0.33 |
| Mar 31, 2023 | -0.16 |
| Dec 31, 2022 | -0.20 |
| Sep 30, 2022 | -0.26 |
| Jun 30, 2022 | -0.60 |
| Mar 31, 2022 | -0.72 |
| Dec 31, 2021 | -1.28 |
| Sep 30, 2021 | -0.76 |
| Dec 31, 2020 | -0.92 |